Role, epidemiology, and natural history of benign uterine mass lesions

Clinical Obstetrics and Gynecology

Volumn 48, Issue 2, 2005, Pages 312-324

  Ryan, Ginny L ^a   Syrop, Craig H ^a   Van Voorhis, Bradley J ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; TAMOXIFEN;

ADULT; BENIGN TUMOR; ENDOMETRIOSIS; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; FEMALE INFERTILITY; HIGH RISK PATIENT; HUMAN; INCIDENCE; MENORRHAGIA; METRORRHAGIA; POSTMENOPAUSE; PREMENOPAUSE; PREVALENCE; REVIEW; RISK FACTOR; SPOTTING; SQUAMOUS CELL METAPLASIA; SYMPTOMATOLOGY; TUMOR GROWTH; UTERUS BLEEDING; UTERUS MYOMA; VAGINA BLEEDING;

FEMALE; HUMANS; LEIOMYOMA; POLYPS; UTERINE DISEASES; UTERINE HEMORRHAGE;

EID: 18044381116     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.grf.0000159538.27221.8c     Document Type: Review

References (69)

1. Van Bogaert LJ. Clinicopathologic findings in endometrial polyps. Obstet Gynecol. 1988;71:771-773.
2. Scott R. The elusive endometrial polyp. Obstet Gynecol. 1953;1:212-218.
3. Tjarks M, Van Voorhis BJ. Treatment of endometrial polyps. Obstet Gynecol. 2000;96:886-889.
4. Benign Gynecologic Lesions. In: Stenchever MA, Droegemueller W, Herbst AL, et al, eds. Comprehensive Gynecology. St. Louis, MO: Mosby; 2001:495-504.
5. Savelli L, De Iaco P, Santini D, et al. Histopathologic features and risk factors for benignity, hyperplasia, and cancer in endometrial polyps. Am J Obstet Gynecol. 2003;188:927-931.
6. Clevenger-Hoeft M, Syrop CH, Stovall D, et al. Sonohysterography in premenopausal women with and without abnormal bleeding. Obstet Gynecol. 1999;94:516-520.
7. Anastasiadis P, Koutlaki NG, Skaphida PG, et al. Endometrial polyps: prevalence, detection, and malignant potential in women with abnormal uterine bleeding. Eur J Gynaecol Oncol. 2000;21:180-183.
8. Goldstein S, Zeltser I, Horan CK, et al. Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding. Am J Obstet Gynecol. 1997;177:102-108.
9. Mittal K, Schwartz L, Goswami S, et al. Estrogen and progesterone receptor expression in endometrial polyps. Int J Gynecol Pathol. 1996;15:345-348.
10. Taylor L, Jackson TL, Reid JG, et al. The differential expression of oestrogen receptors, progesterone receptors, Bcl-2 and Ki67 in endometrial polyps. BJOG. 2003;110:794-798.
11. Dal Cin P, Vanni R, Marras S, et al. Four cytogenetic subgroups can be identified in endometrial polyps. Cancer Res. 1995;55:1565-1568.
12. Bol S, Wanschura S, Thode B, et al. An endometrial polyp with a rearrangement of HMGI-C underlying a complex cytogenetic rearrangement involving chromosomes 2 and 12. Cancer Genet Cytogenet. 1996;90:88-90.
13. Tallini G, Vanni R, Manfioletti G, et al. HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. Lab Invest. 2000;80:359-369.
14. Elmore L, Domson K, Moore JR, et al. Expression of c-kit (CD117) in benign and malignant human endometrial epithelium. Arch Pathol Lab Med. 2001;125:146-151.
15. Maia H, Maltez A, Athayde C, et al. Proliferation profile of endometrial polyps in post-menopausal women. Maturitas. 2001;40:273-281.
16. Orvieto R, Bar-Hava I, Dicker D, et al. Endometrial polyps during menopause: characterization and significance. Acta Obstet Gynecol Scand. 1999;78:883-886.
17. Damjanor JL, ed. Adderson's Pathology. St. Louis, MO: Mosby; 1996.
18. Reslova T, Tosner J, Resl M, et al. Endometrial polyps. A clinical study of 245 cases. Arch Gynecol Obstet. 1999;262:133-139.
19. Peterson W, Novak ER. Endometrial polyps. Obstet Gynecol. 1956;8:40-49.
20. Gardner F, Konje JC, Abrams KR, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet. 2000;356:1711-1717.
21. Hann L, Kim CM, Gonen M, et al. Sonohysterography compared with endometrial biopsy for evaluation of the endometrium in tamoxifen-treated women. J Ultrasound Med. 2003;22:1173-1179.
22. Perrone G, Deangelis C, Critelli C, et al. Hysteroscopic findings in postmenopausal abnormal uterine bleeding: a comparison between HRT users and non-users. Maturitas. 2002;43:251-255.
23. Akkad A, Habiba MA, Ismail N, et al. Abnormal uterine bleeding on hormone replacement: the importance of intrauterine structural abnormalities. Obstet Gynecol. 1995;86:330-334.
24. Kim M, Kim YA, Jo MY, et al. High frequency of endometrial polyps in endometriosis. J Am Assoc Gynecol Laparosc. 2003;10:46-48.
25. Coeman D, Van Belle Y, Vanderick G, et al. Hysteroscopic findings in patients with a cervical polyp. Am J Obstet Gynecol. 1993;169:1563-1565.
26. Frydman R, Eibschitz I, Fernandez H, et al. Uterine evaluation by microhysteroscopy in IVF candidates. Hum Reprod. 1987;2:481-485.
27. Seinera P, Maccario S, Visentin L, et al. Hysteroscopy in an IVF-ER program. Clinical experience with 360 infertile patients. Acta Obstet Gynecol Scand. 1988;67:135-137.
28. Syrop C, Sahakian V Transvaginal sonographic detection of endometrial polyps with fluid contrast augmentation. Obstet Gynecol. 1992;79:1041-1043.
29. Lass A, Williams G, Abusheikha N, et al. The effect of endometrial polyps on outcomes of in vitro fertilization (IVF) cycles. J Assist Reprod Genet. 1999;16:410-415.
30. Varasteh N, Neuwirth RS, Levin B, et al. Pregnancy rates after hysteroscopic polypectomy and myomectomy in infertile women. Obstet Gynecol. 1999;94:168-171.
31. Oliveira F, Abdelmassih VG, Diamond MP, et al. Uterine cavity findings and hysteroscopic interventions in patients undergoing in vitro fertilization-embryo transfer who repeatedly cannot conceive. Fertil Steril. 2003;80:1371-1375.
32. Dewaay D, Syrop CH, Nygaard IE, et al. Natural history of uterine polyps and leiomyomata. Obstet Gynecol. 2002;100:3-7.
33. Goldstein S, Monteagudo A, Popiolek D, et al. Evaluation of endometrial polyps. Am J Obstet Gynecol. 2002;186:669-674.
34. Sullivan L, Sullivan JL, Fairey WF. Breast carcinoma metastatic to endometrial polyp. Gynecol Oncol 1990;39:96-98.
35. Wallach E, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol. 2004;104:393-406.
36. Wegienka G, Baird DD, Hertz-Picciotto I, et al. Self-reported heavy bleeding associated with uterine leiomyomata. Obstet Gynecol. 2003;101:431-437.
37. Stovall D. Clinical symptomatology of uterine leiomyomas. Clin Obstet Gynecol. 2001;44:364-371.
38. Buttram V, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril. 1981;36:433-445.
39. Marino J, Eskenazi B, Warner M, et al. Uterine leiomyoma and menstrual cycle characteristics in a population-based cohort study. Hum Reprod. 2004;19:2350-2355.
40. Bronz L, Suter T, Rusca T. The value of transvaginal sonography with and without saline instillation in the diagnosis of uterine pathology in pre- and postmenopausal women with abnormal bleeding or suspect sonographic findings. Ultrasound Obstet Gynecol. 1997;9:53-58.
41. Wong SF, Wong AYK, Tang LCH. Findings in women with postmenopausal bleeding investigated with hysteroscopy. Obstet Gynecol. 2001;21:392-395.
42. Stewart E. Uterine fibroids. Lancet. 2001;357:293-298.
43. Moorehead ME. Uterine leiomyoma: a treatable condition. Ann NY Acad Sci. 2001;948:121-129.
44. Stewart E, Nowak RA. Leiomyoma-related bleeding: a classic hypothesis updated for the molecular era. Hum Reprod Update. 1996;2:295-306.
45. Sampson J. The blood supply of uterine myomata. Surg Gynecol Obstet. 1912;14:215-230.
46. Faulkner R. The blood vessels of the myomatous uteri. Am J Obstet Gynecol. 1945;47:185-197.
47. Farrer-Brown G, Beilby JO, Tarbit MH. Venous changes in the endometrium of myomatous uteri. Obstet Gynecol. 1971;38:743-751.
48. Ligon A, Morton CC. Leiomyomata: heritability and cytogenetic studies. Hum Reprod Update. 2001;7:8-14.
49. Schwartz S. Epidemiology of uterine leiomyomata. Clin Obstet Gynecol. 2001;44:316-326.
50. Borgfeldt C, Andolf E. Transvaginal ultrasonographic findings in the uterus and the endometrium: low prevalence of leiomyoma in a random sample of women age 25-40 years. Acta Obstet Gynecol Scand. 2000;79:202-207.
51. Cramer S, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol. 1990;94:435-438.
52. Baird DD, Hill MC, Cousins D, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188:100-107.
53. Faerstein E, Szklo M, Rosenshein N. Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive history, body size, and smoking. Am J Epidemiol. 2001;153:1-10.
54. Wise L, Palmer JR, Harlow BL, et al. Reproductive factors, hormonal contraception, and risk of uterine leiomyomata in African-American women: a prospective study. Am J Epidemiol. 2004;159:113-123.
55. Marshall L, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril. 1998;70:432-439.
56. Van Voorhis BJ. The epidemiology of uterine fibroids. Infert Reprod Med Clin N Am. 2002;13:271-281.
57. Reed S, Cushing-Haugen KL, Daling JR, et al. Postmenopausal estrogen and progestogen therapy and the risk of uterine leiomyomas. Menopause. 2004;11:214-222.
58. Ang W, Farrell E, Vollenhoven B. Effect of hormone replacement therapies and selective estrogen receptor modulators in postmenopausal women with uterine leiomyomas: a literature review. Climacteric. 2001;4:284-292.
59. Marshall L, Spiegelman D, Manson JE, et al. Risk of uterine leiomyomata among premenopausal women in relation to body size and cigarette smoking. Epidemiology. 1998;9:511-517.
60. Luoto R, Kaprio J, Rutanen EM, et al. Heritability and risk factors of uterine fibroids - the Finnish Twin Cohort study. Maturitas. 2000;37:15-26.
61. Chen C, Buck GM, Courey NG, et al. Risk factors for uterine fibroids among women undergoing tubal sterilization. Am J Epidemiol. 2001;153:20-26.
62. Lethaby A. Fibroids (uterine myomatosis, leiomyomas). Clin Evid. 2003;7:1666-1678.
63. Donnez J, Jadoul P. What are the implications of myomas on fertility? A need for a debate? Hum Reprod. 2002;17:1424-1430.
64. Van Voorhis B, Romitti PA, Jones MP. Family history as a risk factor for development of uterine leiomyomas. Results of a pilot study. J Reprod Med. 2002;47:663-669.
65. Treloar S, Martin NG, Dennerstein L, et al. Pathways to hysterectomy: insights from longitudinal twin research. Am J Obstet Gynecol. 1992;167:82-88.
66. Kawamura S, Kasagi F, Kodama K, et al. Prevalence of uterine myoma detected by ultrasound examination in the atomic bomb survivors. Radiat Res. 1997;147:753-758.
67. Faerstein E, Szklo M, Rosenshein NB. Risk factors for uterine leiomyoma: a practice-based case-control study. II. Atherogenic risk factors and potential sources of uterine irritation. Am J Epidemiol. 2001;153:11-19.
68. Marshall L, Spiegelman D, Barbieri RL, et al. Variation in the incidence of uterine leiomyoma among premenopausal women by age and race. Obstet Gynecol. 1997;90:967-973.
69. Levy B, Mukherjee T, Hirschhorn K. Molecular cytogenetic analysis of uterine leiomyoma and leiomyosarcoma by comparative genomic hybridization. Cancer Genet Cytogenet. 2000;121:1-8.